Amazines Free Article Archive - Monday, October 02, 2023
Read about the most recent changes and happenings at
Log into your account or register as a new author. Start submitting your articles right now!
Search our database for articles.
Subscribe to receive articles emailed straight to your email account. You may choose multiple categories.
View our newest articles submitted by our authors.
View our most top rated articles rated by our visitors.
* Please note that this is NOT the ARTICLE manager
Add a new EZINE, or manage your EZINE submission.
Add fresh, free web content to your site such as newest articles, web tools, and quotes with a single piece of code!
Home What's New? Submit/Manage Articles Latest Posts Top Rated Article Search
Subscriptions Manage Ezines
 Article Archive
 Advertising (133564)
 Advice (161668)
 Affiliate Programs (34799)
 Art and Culture (73853)
 Automotive (145708)
 Blogs (75610)
 Boating (9851)
 Books (17223)
 Buddhism (4130)
 Business (1330527)
 Business News (426444)
 Business Opportunities (366517)
 Camping (10973)
 Career (72797)
 Christianity (15848)
 Collecting (11638)
 Communication (115088)
 Computers (241949)
 Construction (38960)
 Consumer (49953)
 Cooking (17081)
 Copywriting (6733)
 Crafts (18203)
 Cuisine (7549)
 Current Affairs (20316)
 Dating (45908)
 EBooks (19703)
 E-Commerce (48258)
 Education (185514)
 Electronics (83522)
 Email (6438)
 Entertainment (159849)
 Environment (28952)
 Ezine (3040)
 Ezine Publishing (5453)
 Ezine Sites (1551)
 Family & Parenting (111007)
 Fashion & Cosmetics (196597)
 Female Entrepreneurs (11853)
 Feng Shui (134)
 Finance & Investment (310616)
 Fitness (106469)
 Food & Beverages (63042)
 Free Web Resources (7941)
 Gambling (30227)
 Gardening (25202)
 Government (10517)
 Health (630113)
 Hinduism (2206)
 Hobbies (44083)
 Home Business (91611)
 Home Improvement (251209)
 Home Repair (46241)
 Humor (4721)
 Import - Export (5458)
 Insurance (45104)
 Interior Design (29617)
 International Property (3488)
 Internet (191027)
 Internet Marketing (146687)
 Investment (22861)
 Islam (1161)
 Judaism (1352)
 Law (80504)
 Link Popularity (4596)
 Manufacturing (20912)
 Marketing (99312)
 MLM (14140)
 Motivation (18233)
 Music (26999)
 New to the Internet (9496)
 Non-Profit Organizations (4048)
 Online Shopping (129734)
 Organizing (7813)
 Party Ideas (11855)
 Pets (38167)
 Poetry (2229)
 Press Release (12689)
 Public Speaking (5641)
 Publishing (7565)
 Quotes (2407)
 Real Estate (126644)
 Recreation & Leisure (95491)
 Relationships (87674)
 Research (16182)
 Sales (80348)
 Science & Technology (110287)
 Search Engines (23514)
 Self Improvement (153298)
 Seniors (6220)
 Sexuality (36010)
 Small Business (49310)
 Software (83032)
 Spiritual (23512)
 Sports (116154)
 Tax (7663)
 Telecommuting (34070)
 Travel & Tourism (308272)
 UK Property Investment (3123)
 Video Games (13382)
 Web Traffic (11790)
 Website Design (56918)
 Website Promotion (36662)
 World News (1000+)
 Writing (35844)
Author Spotlight

hello my name is Michael Campbell, I producer music for a living my company name is deal figure ente...more

I'm a full-time Writer, dreamer and chief executive manager. I write to release my true stories in t...more

I am in Nepalest tourism industery working since 2000 as a trekking porter to the senior tour leader...more

Suman Aryal is a skilled tour and trekking operator with expertise in organizing and writing itinera...more

I am an essay writer with vast experience in data analysis, PowerPoint writing and research paper ed...more

Invokana for the treatment Type II diabetes mellitus by Clinnovo Research Labs

Article Author Biography
Invokana for the treatment Type II diabetes mellitus by
Article Posted: 05/24/2013
Article Views: 420
Articles Written: 26
Word Count: 1040
Article Votes: 1
AddThis Social Bookmark Button

Invokana for the treatment Type II diabetes mellitus

Education,Health,Science & Technology
Invokana (canagliflozin) is a sodium-glucose co-transporter 2(SGLT2) inhibitor that got approval from FDA on March 31st2013 for the treatment of Type II diabetes mellitus. Invokana is the first diabetes treatment approved which falls in a new class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. Invokana contains the active ingredient canagliflozin, an inhibitor of sodium-glucose co transporter 2 (SGLT2). SGLT2 is a member of the sodium glucose co-transporter family which are sodium-dependent glucose transport proteins. SGLT2 is the major co-transporter involved in glucose reabsorption in the kidney. Invokana works by blocking the reabsorption of glucose by the kidney thus increasing glucose excretion and lowering blood glucose levels. Its safety and effectiveness were evaluated in nine clinical trials involving total 10,285 patients with type 2 diabetes who manifested improvement in hemoglobin A1c levels and fasting plasma glucose levels.

The hemoglobin A1c test also known as glycated hemoglobin test or glycohemoglobin test is an important blood test used to determine how well a patient’s diabetes is being controlled. Hemoglobin A1c provides an average of blood sugar control over a six to 12 week period and is used in conjunction with home blood sugar monitoring. When the sugar level is high it combines with hemoglobin, becoming "glycated." Therefore, the average amount of sugar in blood can be determined by measuring a hemoglobin A1c level. Inhibiting SGLT2 is believed to reduce blood glucose levels by increasing the amount of glucose excreted in the urine. Invokana is specifically indicated as an adjunct to diet and used to improve glycemic control in adults with type 2 diabetes mellitus.

Diabetes mellitus type 2 (formerly known as noninsulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes) is a metabolic disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. Type 2diabetes is initially managed by increasing exercise and dietary modifications. If blood glucose levels are not adequately lowered by applying these measures, medications should be used. The classic symptoms are excess thirst, frequent urination, and constant hunger. Obesity is thought to be the primary cause of type2 diabetes in people who are genetically predisposed to the disease. Long-term complications from high blood sugar could include heart disease, stroke, diabetic retinopathy(eyesight is affected), kidney function failure leading to dialysis, poor circulation of limbs leading to even amputations. Controlling blood sugar is the key to prevent the side effects caused by diabetes, such as vision loss, nerve damage, kidney damage and increased risk of heart attack and stroke. Type 2diabetes comprises of about 90% of cases of diabetes with the other 10% due primarily to diabetes mellitus type 1 and gestational diabetes.

Commonly, the newly diagnosed diabetes patients are prescribed with metformin (Glucophage, Glumetza, others), a diabetes medication that improves tissues' sensitivity to insulin and lowers glucose production in the liver. At this stage doctors also recommend lifestyle changes, such as losing weight and becoming more active. When metformin is not enough to control glucose level, other oral or injected medications are used to treat type 2 diabetes. Medications lower glucose in different ways. Some diabetes medications stimulate the pancreas to produce and release more insulin. These include glipizide (Glucotrol), glyburide (Diabeta, Glynase) and glimepiride (Amaryl).While others block the action of enzymes that break down carbohydrates in the intestine, such as acarbose (Precose).

Invokana is the first diabetes treatment approved in a new class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. It contains canagliflozin, an inhibitor of sodium-glucose co transporter 2 (SGLT2), the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. It is available as film-coated tablets for oral administration, containing 102 and 306 mg of canagliflozin in each tablet strength, corresponding to 100 mg and 300 mg of canagliflozin (anhydrous), respectively. The recommended starting dose of Invokana is 100 mg once daily which has to be taken before the first meal of the day. In patients tolerating Invokana 100 mg once daily who have an EGFR of 60 mL/min/1.73 m2 or greater and require additional glycemic control, the dose can be increased to 300 mg once daily.

Invokana (canagliflozin) is a sodium-glucose co-transporter 2(SGLT2)inhibitor. Sodium-glucose co-transporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG), and thereby increases urinary glucose excretion.

The FDA approval of Invokana was based in part on a monotherapy study. Invokana was also studied in combination with metformin, sulfonylurea, metformin and sulfonylurea, metformin and thiazolidinedione and in combination with insulin (with or without other antihyperglycemic agents). The efficacy of Invokana was compared to a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin) and a sulfonylurea (glimepiride).In Phase III studies, Invokana manifested reduction in body weight and systolic blood pressure in the patients.

The important side effects caused by this drug include dehydration which may cause dizziness, fainting, light headedness, or weak feeling especially in standing position. This drug also predisposes to Yeast infections in the genitals for both men and women and urinary tract infections (UTIs).

Invokana should not be used for patients with Type 1 diabetes and Diabetic ketoacidosis in which ketones are present in urine or blood. According to the FDA Janssen Pharmaceuticals, Inc. (part of Johnson & Johnson) will have to carry out post-marketing studies on cardiovascular outcomes to check for liver abnormalities, photosensitivity reactions, adverse pregnancy outcomes, malignancies, severe hypersensitivity reactions and serious cases of pancreatitis.

Thus Invokana has got approval from FDA on the basis efficacy data manifested by this drug till date. The future study reports will conclude if this drug will remain in market for long term treatment and could be a future “blockbuster” for the treatment of type II Diabetes.

Clinnovo is a clinical innovation company. It is pioneer CRO industry in India. Clinnovo offers professional Clinical Research Course, clinical data management course , SAS and imaging training. Clinnovo has been serving different bio-pharma industries across the world with excellence and high quality. For more information contact at +91 9912868928, 040 64635501

Related Articles - clinical trial, Invokana, diabetes type 2, diabetes treatment, new diabetes treatment, Treatment for diabetes type 2, blood sugar control,

Email this Article to a Friend!

Receive Articles like this one direct to your email box!
Subscribe for free today!

 Rate This Article  
Completely useless, should be removed from directory.
Minimal useful information.
Decent and informative.
Great article, very informative and helpful.
A 'Must Read'.


Do you Agree or Disagree? Have a Comment? POST IT!

 Reader Opinions 
Submit your comments and they will be posted here.
Make this comment or to the Author only:
*Your email will NOT be posted. This is for administrative purposes only.
Comments: *Your Comments WILL be posted to the AUTHOR ONLY if you select PRIVATE and to this PUBLIC PAGE if you select PUBLIC, so write accordingly.
Please enter the code in the image:

 Author Login 
Register for Author Account


Advertiser Login


   Limited Time $60 Offer!
   90  Days-1.5 Million Views  


Great Paranormal Romance


At LeadGenerators, we specialise in content-led Online Marketing Strategies for our clients in the t...more

I am the editor of QUAY Magazine, a B2B publication based in the South West of the UK. I am also the...more

After 60-plus years of living, I am just trying to pass down some of the information that I have lea...more

Steve Bye is currently a fiction writer, who published his first novel, ‘Looking Forward Through the...more

A postgraduate in Fashion Technology. Shalini is a writer at heart! Writing for her is an expression...more

James is a Research Enthusiast that focuses on the understanding of how things work and can be impro...more

Stevert Mckenzie, Travel Enthusiast. ...more

Author of four books and two screenplays; frequent magazine contributor. I have four other books "in...more

I have been involved in nutrition and weight management for over 12 years and I like to share my kn...more

Ryan Jones owns and operates this website, Having worked in the computer industry sin...more

HomeLinksAbout UsContact UsTerms of UsePrivacy PolicyFAQResources
Copyright © 2023, All rights reserved.
Some pages may contain portions of text relating to certain topics obtained from under the GNU FDL license